Introduction

Relapse of drug use following a prolonged period of drug cessation is a key barrier to addiction treatment [1, 2] and is an important characteristic of METH users [3]. However, there are currently no United States Food and Drug Administration (FDA)-approved pharmacotherapies for treatment of METH addiction [4]. Successful relapse prevention must be based on an understanding of the neurobiological mechanisms of drug relapse [5].

To explore the neurobiological mechanisms of this complex behavioral phenomenon, in vivo models have been utilized in combination with functional, neurochemical, and electrophysiological techniques [5, 6]. The drug reinstatement procedure in rats is a pre-clinical model of reinstatement in humans [7]; rats are trained using a conditioned place preference (CPP) paradigm that includes re-exposure to environmental contexts paired with a drug [8].

Emerging evidence reveals that activation of hippocampal glutamate receptors is directly implicated in reinstatement of psychostimulant seeking [9, 10], which glutamate receptors are interplay with changes in synaptic plasticity [11]. Hippocampal synaptic plasticity is bi-directionally modulated by psychostimulant self-administration [12]. Thus, the hippocampus is critical to studying the potential rewarding properties of METH and memory [13,14,15,16] and the contributions to reinstatement of psychostimulant seeking behavior [17]. Furthermore, inactivation of hippocampal outputs attenuates psychostimulant seeking associative cues [18, 19]. Additionally, developmental disruption of hippocampal connectivity increases psychostimulant self-administration [20].

Drug-induced changes in serum brain-derived neurotrophic factor (BDNF) in the cortex and hippocampus have been observed in METH users [21]. However, the source of BDNF changes and the relevance of these changes to the onset and maintenance of addiction have not been elucidated [22]. Reports on the role of psychostimulant administration on BDNF are often contradictory [23, 24]. Also, there is evidence that BDNF is a critical regulator of the late protein synthesis-dependent stage of LTP neurotransmitter release [25], thereby promoting LTP [26]. Additionally, BDNF is essential to regulation of activity-dependent pre-synaptic vesicle cycling, which is dependent on N-methyl D-aspartate (NMDA) receptor activation in cultured neocortical neurons from BDNF-knockout mice [27]. Furthermore, increasing of BDNF is associated with enhancing of NMDA expression and intracellular calcium concentrations [28, 29], thereby promoting long-term changes to synaptic activity.

To clarify paradoxical findings regarding the effects of psychostimulants on BDNF and LTP [27, 30], and to detect the mechanism of drug reinstatement, we administered different doses of METH to reinstated rats. The understanding of the mechanisms of METH relapse could lead to therapeutic options for patients with METH addiction.

Methods

Animals

Thirty-two adult male albino Wistar rats (8 weeks of age; 220 ± 20 g) were purchased from the animal house at the Hamadan University of Medical Science. The animals were maintained in groups of four per cage in a 12-h light/dark cycle (light on 7:00 a.m. and off 7:00 p.m.) in a room with controlled temperature, and received ad libitum access to food and water. All rats were allowed to adapt to their new environment and had regular handling for at least 1 week before the start of the experiment. Animal protocols were approved by the ethics committee of the Hamadan University of Medical Sciences (IR.Umsha.REC.1394.200), and performed according to the Guide for Care and Use of laboratory animals published by the National Institute of Health, United States (NIH Publication No. 85-23, revised 1985).

Drugs

METH (Drug Control Headquarters of the Police, Iran) was dissolved in saline and prepared fresh every day for intraperitoneal injection. Urethane was purchased from Sigma-Aldrich (Germany). Anti-BDNF monoclonal antibody, horseradish peroxidase (HRP), the Western Blotting Substrate Kit, and β-actin antibodies were purchased from Abcam (Cambridge, UK).

Apparatus for place conditioning and behavioral measurements

The CPP apparatus was made of Plexiglas which comprised 2 equal-sized chambers (30 cm × 30 cm × 40 cm) attached by a removable wall to a third section (30 cm × 15 cm × 40 cm) that served as the null compartment. The lateral compartments had white walls with black stripes in different orientations (vertical vs horizontal), differently textured floors (smooth or net-like), and different environmental cues [31, 32]. In this apparatus, rats showed no consistent preference for any of the large compartments in the pretest, which supports our unbiased CPP paradigm. CPP protocol was conducted on 23 consecutive days and included 5 different phases: preconditioning, conditioning, post-test, extinction, and reinstatement.

The reinstatement model was developed as previously described [33, 34]. Following the pretest, animals were equally and randomly assigned to receive METH (1, 5, or 10 mg/kg, n = 8; as low, medium, and high doses, respectively). According to previous research, the dose–response relationship for METH in CPP was used (dose 1 [35, 36], dose5 [37,38,39,40] and dose 10 [41, 42]) for 7 consecutive days of twice daily sessions exposed to one distinct chamber, and an alternative chamber in the presence of vehicle, with this assignment remaining fixed for the duration of the experiment for a half hour. During the post-test phase and the following day (extinction phase), each rat was placed in the middle chamber of the apparatus (no injections given) for 10 min: animals were given free access to both chambers. Conditioning scores were recorded using a published formula [43]; the time spent in the METH-paired compartment was subtracted from the time spent in the saline-paired chamber. Following the test, each rat was placed in the conditioning chamber for 30 min with a different dose METH injection before the guillotine doors were lifted on the last day of extinction. The control group received saline as a vehicle group. Finally, conditioning scores were recorded on the reinstatement phase during a 10-min period [44].

Electrophysiology

Following implementation of the reinstatement model, we assessed the population spike (PS) amplitude and field excitatory postsynaptic potential (fEPSP) slope using an electrophysiological procedure [45, 46]. Rats were anesthetized by injection of urethane (1.5 g/kg; intraperitoneal, i.p.) and the head was placed in a stereotaxic apparatus. Two small holes were drilled in the skull and the bipolar stimulation and recording electrodes were positioned in the perforant pathway and the dentate gyrus (DG) based on the Paxinos and Watson Atlas [47]. After a steady state was achieved, the stimulation intensity was regulated to evoke approximately 80% of the maximal EPSP response and the slope of the PS amplitude, using high frequency stimuli (HFS) protocols of 400 Hz (10 bursts of 20 stimuli, 0.2 ms stimulus duration, 10 s interburst interval) for 5, 30, and 60 min after HFS [48]. Data were analyzed using Biochart software. The value of LTP was described as: LTP = the value of EPSP or PS after HFS induction/the average value of EPSP or PS at baseline × 100% [49, 50].

Western blotting

Immediately following LTP recordings, some animals were sacrificed by rapid decapitation, and the hippocampus was removed and immediately frozen in liquid N2. The western blotting method was performed as in previous study procedures [29, 51, 52].

The right frozen hippocampi were homogenized with 200 μl of lysis buffer [RIPA buffer and the inhibitor cocktail 1:20] for 1 h and centrifuged at 12,000 g at 4 °C for 20 min. Protein concentration was determined with the Bio-Rad protein assay, and 100 µg of the total protein from each sample was denatured with the sample buffer (6.205 mM tris–HCl, 10% glycerol, 2% SDS, 0.01% bromophenol blue, and 50 mM 2-ME) at 95 °C for 5 min.

The denatured proteins were separated using SDS-PAGE (10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis) and were transferred to a nitrocellulose membrane. Nonspecific binding (NSB) were blocked with 5% nonfat dry milk (NFDM), and the membranes were probed using anti-brain-derived neurotrophic factor (BDNF) (1:500), and β-actin (1:1000) monoclonal antibodies for 2 h, and the anti-rabbit secondary antibodies (1:5000) were conjugated to horseradish peroxidase for 1 h. The bands were detected using 5-bromo-4-chloro-3-indolyl phosphate in the presence of nitroblue tetrazolium as a chemiluminescent substrate. Density of the band was measured through an image analysis system (UVIdoc, Houston, TX, USA). β-actin antibody was used as a normalization control.

Apoptosis (TUNEL assay)

For histological study, the brains of anesthetized rats from the electrophysiology test were fixed through perfusion with a paraformaldehyde solution. The brains were dehydrated, embedded in paraffin, and sliced into a series of coronal sections of 5 μm thickness according to previous studies [47, 53].Then, sections were used for TdT-mediated dUTP end labeling (TUNEL) staining, in which DNA fragmentation and apoptosis were detected by a TUNEL Detection Kit (Abcam) following the manufacturer’s instructions. After staining, the sections were analyzed under a light microscope (× 400, Olympus). An apoptotic neuron in the hippocampal cornu ammonis1 (CA1) region showed brown colored units in the nucleus.

Statistical analyses

Data were analyzed using SPSS v16 software (IBM, Armonk, USA). CPP conditioning scores, PS amplitudes, and EPSP slopes were analyzed with one- and two-way ANOVAs. A Tukey post-hoc test was used where pairwise comparisons were performed. Furthermore, BDNF protein densities and TUNEL assay were evaluated using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc tests for comparisons between groups. Data are expressed as means ± standard errors of the mean (SEMs). Statistical significance was determined by P < 0.05 for all experiments.

Results

Dose effects of METH on reinstatement of METH-induced CPP

The effects of METH (1, 5, or 10 mg/kg; i.p.) on the CPP paradigm were investigated. A two-way ANOVA for behavioral test showed significant effects between groups [F(3, 28) = 30.46, P < 0.001], time [F (1, 32) = 42.31, P < 0.001], and their interaction [F(3, 28) = 16.03, P < 0.001].

Figure 1a shows no significant differences in conditioning scores between any METH group on the pretest (one-way ANOVA) [F(3, 28) = 0.207, P = 0.890]. [Control: 29.49 ± 6.37, METH (1 mg/kg): 30.13 ± 9.28, METH (5 mg/kg): 39.59 ± 8.76, METH (10 mg/kg): 37.66 ± 6.95). However, there were significant differences between the control (saline) and experimental groups (5, and 10 mg/kg) conditioning scores for the reinstatement phase (day 23). Time spent in the METH-paired chamber did not differ from time spent in the saline chamber in the METH (1 mg/kg) group (41.38 ± 5.69) compared to the control group (26.4 ± 4.78). Moreover, one-way ANOVA followed by Tukey’s post hoc tests revealed that conditioning score in the 5 mg/kg METH group was significantly higher than that in the other groups during a 10-min period [F(3, 28) = 114.81, P < 0.001]. Conditioning scores in the 10 mg/kg METH group were significantly lower than that in the 5 mg/kg METH group (P < 0.001). [METH (5 mg/kg): 139.86 ± 11.07, METH (10 mg/kg): 77.92 ± 5.71].

Fig. 1
figure 1

Effects of exposure to different doses of methamphetamine (METH) place preference on the pretest and reinstatement day in rats. There were no significant differences in conditioning scores between any METH groups with control group on the pretest (a; n = 8 in each group). On the reinstatement day, the preference score of 10 mg/kg METH vs 5 mg/kg METH group was significant (♠♠♠P < 0.001). The preference scores of METH 5 and 10 mg/kg vs the other groups were significant (***P < 0.001 and *P < 0.05, respectively; a). Moreover, a comparison of pretest and reinstatement days in METH 5 and 10 mg/kg showed significant differences (&&&P < 0.001). Also, different doses of METH did not alter the locomotor activity in comparison with the control group (n = 8 in each group; b)

Full size image

Also, paired t-tests indicated that preference scores significantly changed on reinstatement day compared to the pretest among experimental groups (METH 5 and 10 mg/kg): control (P = 0. 834), METH 1 mg/kg (P = 0.260), METH 5 mg/kg (P = 0.000), METH 10 mg/kg (P = 0.009; Fig. 1a).

Additionally, different doses of METH did not alter the distance traveled between groups [F(3, 28) = 2.1, P = 0.12], time [F(1, 32) = 0.66, P = 0.42], or their interaction [F(3, 28) = 0.9, P = 0.45; Fig. 1b]. Pretest [Control: 1473.10 ± 159.04, METH (1 mg/kg):1487.17 ± 146.64, METH (5 mg/kg):1593.37 ± 291.59, METH (10 mg/kg): 1266.87 ± 112.37]. Reinstatement [Control: 1350.87 ± 121.99, METH (1 mg/kg): 1420.53 ± 135.20, METH (5 mg/kg): 1905.30 ± 309.35, METH (10 mg/kg): 1494.87 ± 170.11]. The reinstatement animal model was achieved after 23 days.

Effects of METH administration on PS amplitudes in granular cells of the hippocampal DG in reinstated rats

Figure 2a shows that the difference in the voltage between the peaks of the first positive and negative waves was defined as the amplitude of the PS. The fEPSP slope was measured as the maximum slope of the initial portion of the response. Figure 2b presents an example of sample traces of responses taken before and after HFS in each group. Figure 3 illustrates the effects of METH on PS amplitudes in DG granular cell synapses on reinstatement day. The PS amplitude was significantly higher in the 5 mg/kg METH group than in all other groups. A two-way ANOVA of PS amplitude showed significant difference between groups [F(3, 28) = 35.91; P < 0.001], time [F(3, 96) = 74.33, P < 0.001], and their interaction [F(9, 84) = 17.6, P < 0.001].

Fig. 2
figure 2

Sample traces of PS amplitude and fEPSP slope recorded prior to and after HFS in pathway perforant to dentate gyrus. Arrows indicate PS amplitude and the slope of the EPSP (a). Evoked field potentials in the DG recorded before and after HFS in all groups are shown in (b)

Full size image
Fig. 3
figure 3

The mean of the population spike (PS) amplitude in dentate gyrus granule cells following a 400-Hz high-frequency stimulus applied to the perforant pathway. Tukey’s post hoc tests indicated that the PS amplitude in the 5 mg/kg methamphetamine (METH) group was significantly higher than those in all other groups at all assessment times. Additionally, PS amplitudes were lower in the 10 mg/kg METH group at all time points than in the 5 mg/kg METH group (P < 0.001). One-way analysis of variance revealed significant effects at the 5 min and 30 min time points for comparisons between 10 mg/kg METH, 1 mg/kg METH, and control groups; the PS amplitudes in granular cells of dentate gyrus decreased (***P < 0.001 5 mg/kg METH vs control and 1 mg/kg METH group), !!!P < 0.01 (10 mg/kg vs 5 mg/kg METH, $P and $$P < 0.05 and 0.01, respectively, 10 mg/kg vs 1 mg/kg METH)

Full size image

Also, one-way ANOVA indicated significant differences in the PS amplitude at 5 min [F(3, 28) = 37.68, P < 0.001], 30 min [F(3, 28) = 32.099; P < 0.001], and 60 min [F(3, 28) = 20.959; P < 0.001]. Furthermore, PS amplitudes were lower at all time points in rats receiving the high dose of METH (10 mg/kg) than in the other groups. One-way ANOVA revealed a significant effect of time points (5 min; P < 0. 01) and (30 min; P < 0. 05) between the 10 mg/kg METH and 1 mg/kg METH groups; PS amplitudes in the DG granular cells were decreased in the 10 mg/kg METH group [Control (5 min: 164.24 ± 15.9, 30 min: 174.39 ± 11.43, or 60 min: 161.60 ± 12.26), METH (1 mg/kg): (5 min: 235.87 ± 19.45, 30 min: 217.46 ± 23.94, or 60 min: 214.02 ± 28.88), METH (5 mg/kg): (5 min: 390.54 ± 28.68, 30 min: 414.91 ± 36.85, or 60 min: 411.18 ± 43.73), METH (10 mg/kg): (5 min:118.40 ± 7.18, 30 min: 113.80 ± 8.35, or 60 min: 136.79 ± 6.52)].

Effects of METH administration on EPSP slopes in DG granular cells of reinstated rats

A two-way ANOVA of EPSP slope revealed significant differences between groups [F(3, 28) = 3.36; P < 0.05], time [F(3, 96) = 8.3, P < 0.001], and their interaction [F(9, 84) = 2.69, P < 0.01]. After HFS, Tukey’s post hoc tests revealed that the EPSP slopes in the 5 mg/kg METH group were significantly greater than for other groups at the 60-min recording time [F(3, 28) = 6.60; P < 0. 01; Fig. 4]. There was no significant difference between groups at the 5-min [F(3, 28) = 1.470; P = 0.244] or 30-min [F(3,28) = 2.471; P = 0.082] recording times [comparisons between control and other groups, P = 1.0; METH (1 mg/kg) compared to METH (5 mg/kg) P = 0.248; METH (1 mg/kg) compared to METH (10 mg/kg) P = 1]. [Control (5 min: 110.42 ± 5.22, 30 min: 101.94 ± 4.89, or 60 min: 105.66 ± 7.73), METH (1 mg/kg): (5 min: 125.59 ± 15.92, 30 min: 102.37 ± 11.26, or 60 min: 103.69 ± 8.24), METH (5 mg/kg): (5 min: 133.59 ± 13.01, 30 min: 124.94 ± 7.43, or 60 min: 144.40 ± 10.16), METH (10 mg/kg): (5 min: 105.64 ± 3.28, 30 min: 99.48 ± 4.84, or 60 min: 101.8 ± 4.59)].

Fig. 4
figure 4

Mean excitatory post-synaptic potential (EPSP) slope in dentate gyrus granule cells following 400-Hz high-frequency stimulus applied to the perforant pathway. There were no significant differences between groups, except at 60 min, when the EPSP slope for the 5 mg/kg methamphetamine group was significantly greater than that for the other groups (**P < 0. 01, n = 8)

Full size image

Effects of METH administration on BDNF expression in the hippocampus of reinstated rats

There was a significant increase in BDNF expression in the 5 mg/kg METH group compared with the control group (P < 0.01). BDNF expression was lower in the 10 mg/kg METH group than in the 5 mg/kg METH and other groups (P < 0.001, 0.01 respectively; Fig. 5). [Control: 0.6833 ± 0.038, METH (1 mg/kg): 0.71 ± 0.036, METH (5 mg/kg): 0.93 ± 0.036 METH (10 mg/kg): 0.48 ± 0.036).

Fig. 5
figure 5

The mean values (± standard errors of the mean) of brain-derived neurotrophic factor (BDNF) protein concentration in the hippocampus were assessed for different methamphetamine (METH) groups. There was a significant difference in higher BDNF expression for the 5 mg/kg METH group than in the control and 1 mg/kg METH groups (P < 0. 01). BDNF expression was lower in the 10 mg/kg METH group than in the 5 mg/kg METH group, the 1 mg/kg METH group, and the control group (P < 0.001). There were no differences in BDNF expression between the 1 mg/kg METH group and the control group (**P < 0.01; 5, and 10 mg/kg METH vs 1 mg/kg METH and control, !!!P < 0.001 10 mg/kg vs 5 mg/kg METH, n = 8)

Full size image

Effects of injection of METH on hippocampal CA1 cells

Figure 6a displays a neuronal section of the CA1 hippocampus of the experimental groups. One-way ANOVA indicated a significant difference in the number of apoptotic cells between groups (P < 0.001). Tukey’s test showed that the brain sections of the rats in the METH group (10 mg/kg) contained more apoptotic neurons than those in the control group (P < 0.001). The mean number of apoptotic neurons in the brain sections in the METH group (5 mg/kg) was significantly decreased compared to the control rats (P < 0.01). There was no significant difference in apoptotic neurons counted between the control and METH (1 mg/kg) group (Fig. 6b).

Fig. 6
figure 6

Light micrographs of cell apoptosis in the hippocampal CA1 region. a Sections derived from a: control; b: METH (1 mg/kg); c: METH (5 mg/kg); and d: METH (10 mg/kg) groups stained by TUNEL. The arrow shows an apoptotic neuron. The mean percentage of apoptotic cells was measured (b) **P < 0.01 as compared with the control group, $$$P < 0.001 as compared with the METH (5 mg/kg) group. Each column represents mean ± SEM. Scale bar = 50 μm, magnification: × 400

Full size image

Discussion

This study investigated the effects of different doses of METH on BDNF expression and long-term potentiation (LTP) and cell apoptosis in the hippocampus of reinstated rats. There were significant differences in the studied parameters between the control (saline) and moderate or high METH experimental groups (5 and 10 mg/kg) during the reinstatement phase. The primary findings are as follows: (1) conditioning scores, LTP, and BDNF expression in the 5 mg/kg METH group were significantly higher than those in the other groups, (2) these parameters were significantly reduced with 10 mg/kg METH compared to 5 mg/kg METH, and sometimes also compared to other groups, and (3) there is an interplay between alterations in LTP and BDNF expression. (4) Intraperitoneal injection of 10 mg/kg METH caused neuronal death in the hippocampus area, while (5) METH (5 mg/kg) decreased neuronal death in this area.

There is evidence that neurotrophins contribute to neuronal plasticity [54, 55]. LTP is the most widely used paradigm to study cellular and molecular events underlying neuronal plasticity [45, 56]. Therefore, we used this paradigm in the dentate-perforant pathway of reinstated rats, and hippocampal BDNF expression was assessed using western blotting to evaluate whether BDNF contributes to drug seeking behavior interplay with LTP. Previous research has demonstrated that drug addiction behavior for psychostimulants is established and maintained via BDNF-dependent mechanisms [57, 58]. The CPP paradigm is widely used to assess associations between drugs and the context in which they are experienced, and it is used as an animal model to assess drug reward and reinstatement [4].

In our first study, CPP conditioning scores (drug seeking behavior) and BDNF expression were compared between the control and experimental groups on the reinstatement day. Our results indicate that METH (1 mg/kg) did not produce significantly different conditioning scores or BDNF expression compared to the control group. This finding contrasts with Shen et al., who found that a lower dose of d-AMP significantly reinstated CPP, and that polymerase chain reaction for BDNF mRNA demonstrated a significant increase after reinstatement [57]. Furthermore, conditioning scores and BDNF expression in their 5 mg/kg group was significantly higher than those in the other groups. Consistent with our study, Corominas et al. found that repeated cocaine administration increases BDNF expression and enhances activity in intracellular pathways (PI3 K and MAPK/ERK) in reward-related brain areas for several days following withdrawal [59]. In contrast to our results, Berglind et al. reported that exogenous intra-dmPFC infused with BDNF suppressed cocaine-seeking after 22 h or 6 d of abstinence, including during tests of cue-induced and cocaine prime-induced reinstatement [60]. However, Pu et al. showed the elevated BDNF expression in the ventral tegmental area after cocaine withdrawal is associated with drug craving and reinstatement [61].

Although BDNF has been proposed as a contributor to drug reward and reinstatement, the role of BDNF in drug-seeking behavior may be more diverse and complex than previously thought, and these enhanced roles have not yet been elucidated [58, 62]. Therefore, we investigated the role of synaptic plasticity on BDNF during relapse behavior. BDNF is a central mediator of activity-dependent plasticity, through which environmental experiences such as sensory information are translated into the structure and function of neuronal networks [25]. Late-phase LTP (L-LTP) requires new protein synthesis of BDNF as a neurotransmitter modulator; as a result, connections between neurons at synapses change in strength [54]. Additionally, during bilateral communication, HFS-induced LTP also occurs, which produces a time-dependent increase in BDNF mRNA levels within dentate granule cells for approximately 30 min, with levels returning to baseline by 4 h [63]. Although there is strong evidence for a critical role of BDNF in L-LTP and long-term memory, many issues have not been resolved [54].

The present results demonstrated that conditioning scores, LTP, and BDNF expression in the 10 mg/kg METH group were lower than those in the 5 mg/kg METH group. Also, apoptosis of hippocampus cells in the METH (10 mg/kg) rats was increased compared with METH (5 mg/kg). Comparison between medium and high doses of METH in the other studies showed that injection of moderate METH significantly increased LTP [45] and level of BDNF expression in the serum and frontal cortex [64], probably via increasing release of neurotransmitters [45]. Also, in comparison with earlier research, injection of high doses of METH, including 10 mg/kg/four times at 2-h intervals, or a single dose of 40 mg/kg, led to decreased LTP in the CA1 of mouse hippocampus [27], increasing cell apoptosis [65]. These are in accordance with the present results. The high dose of METH that decreased LTP may due to increased apoptosis. Furthermore, it has been reported that a high concentration of METH reduces hippocampal LTP (maladaptive plasticity) and neurogenesis, and following it there was extended access expression of BDNF in the hippocampus which is necessary for blocking METH-induced neuronal death [66]. However, some research has focused on direct injection of BDNF into brain nuclei and its effects on search behavior [67]. A previous finding showed injection of doses of toxic METH (high dose, probably) facilitated BDNF synthesis or prevention of degradation of BDNF through dopamine and/or glutamate receptors [68], which appears to be contrary to our result. This controversy may due to the protocol of the experiment. For example, duration and times of injections, kind of injection (ICV, I.P., SC), chronic or acute may cause contrary results. The present study is the first study in this field. Therefore, there is not enough information about the effect of high doses on BDNF reduction compared to a dose of METH (5 mg/kg). Further research may determine the reasons for these effects of different doses of METH.

It is possible that psychostimulants alter synaptic plasticity in the brain, which may partly account for their adverse effects. Previously, it was thought that psychostimulants can induce both increases and decreases in hippocampal LTP, depending on the applied concentration [30, 69]. The decrease in LTP following high concentrations of cocaine may be due to blockade of sodium and and calcium channels, or blockade of large-conductance dependent potassium channels [12, 70, 71]. Thus, we did not expect to find no effect in LTP at lower doses of METH; contrary to previous findings [27], our results demonstrate that differences in LTP did not occur in the hippocampus of the 1 mg/kg METH group compared to the control group.

BDNF is implicated in long-term synaptic plasticity in the adult hippocampus, although the cellular mechanisms are not well-understood [55]. Our results suggest that LTP, and BDNF expression increased in the hippocampus of the 5 mg/kg METH group. Initially, in vitro studies indicated that exogenous BDNF promotes LTP induction by enhancing synaptic responses to tetanic stimulation in young hippocampal slices [72]. In contrast, another study demonstrated that LTP was attenuated in slices pre-treated with function-blocking BDNF antibodies or a molecular scavenger of endogenous BDNF [73].

Our result showed that METH (5 mg/kg) decreased neuronal death in the hippocampus, while METH (10 mg/kg) increased this factor. Another study showed that a single injection of METH (40 mg/kg) caused cell death in the striatum, cortex, and hippocampus [74]. Also, a single high dose of 30 mg/kg METH induced apoptosis of nearly 25% of striatal neurons [75].

Conclusion

In summary, our findings suggest that METH reinstatement affects excitatory synaptic transmission, likely via alterations in BDNF protein expression and neuronal death. METH has dose-dependent effects on BDNF expression and LTP. Additional histological and behavioral experiments related to memory, such as T-maze tests, should be conducted to elucidate the mechanisms and effects of METH on reinstatement induction. Enhanced understanding of the mechanisms of drug relapse will contribute to development of novel treatment strategies for people who wish to cease use.